These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 19018683

  • 1. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Jones RL.
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
    [Abstract] [Full Text] [Related]

  • 2. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
    Goey AK, Schellens JH, Beijnen JH, Huitema AD.
    Ned Tijdschr Geneeskd; 2010 Nov; 154():A1155. PubMed ID: 20619024
    [Abstract] [Full Text] [Related]

  • 3. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR, Spencer CM.
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [Abstract] [Full Text] [Related]

  • 4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L, Bramwell V, Moran LA.
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M, Vici P.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [Abstract] [Full Text] [Related]

  • 7. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    van Dalen EC, Caron HN, Kremer LC.
    Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
    Cvetković RS, Scott LJ.
    Drugs; 2005 May; 65(7):1005-24. PubMed ID: 15892593
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cytoprotective agents for anthracyclines.
    Dorr RT.
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Strategies for reduction of anthracycline cardiac toxicity.
    Speyer J, Wasserheit C.
    Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.